Theravance Biopharma, Inc. (TBPH)
16.64
+0.04
(+0.21%)
USD |
NASDAQ |
Apr 15, 16:00
16.64
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Research and Development Expense (Annual) : 35.91M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Integer Holdings Corp. | 46.35M |
| QuidelOrtho Corp. | 186.20M |
| Catalyst Pharmaceuticals, Inc. | 12.71M |
| Relmada Therapeutics, Inc. | 26.88M |
| Avalo Therapeutics, Inc. | 50.08M |